ArticleJournal of clinical microbiology2005
Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods.
Article in Journal of clinical microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 55 citations in OpenAlex.
- Performance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 againstJAC-antimicrobial resistance · 2026Article
- Antifungal Susceptibility Trends Among Filamentous Fungi: An Epidemiological Evaluation onAntibiotics (Basel, Switzerland) · 2026Article
- Termiticidal Effects and Morpho-Histological Alterations in the Subterranean Termite (Nanomaterials (Basel, Switzerland) · 2024Article
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.Journal of clinical microbiology · 2018Article
- Comparative Evaluation of Sensititre YeastOne and CLSI M38-A2 Reference Method for Antifungal Susceptibility Testing of Aspergillus spp. against Echinocandins.Journal of clinical microbiology · 2017Article
- Scedosporium apiospermum infections and the role of combination antifungal therapy and GM-CSF: A case report and review of the literature.Medical mycology case reports · 2016Article
- Cytotoxicity of voriconazole on cultured human corneal endothelial cells.Antimicrobial agents and chemotherapy · 2011Article
- Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.Clinical microbiology reviews · 2011Review
- Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.International journal of hematology · 2008Article
- In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans.Antimicrobial agents and chemotherapy · 2008Article
- Infections caused by Scedosporium spp.Clinical microbiology reviews · 2008Review
- Update on the treatment of disseminated fusariosis: Focus on voriconazole.Therapeutics and clinical risk management · 2007Article
- Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.Journal of clinical microbiology · 2006Article
- Voriconazole in the management of nosocomial invasive fungal infections.Therapeutics and clinical risk management · 2006Article
- Endophthalmitis caused by Fusarium proliferatum.Journal of clinical microbiology · 2005Article
- In vitro activity of voriconazole against Prototheca wickerhamii: comparative evaluation of sensititre and NCCLS M27-A2 methods of detection.Journal of clinical microbiology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing number of fungal infections, coupled with emerging resistance to classical antifungal agents, has led to the development of new agents, among them voriconazole. Susceptibility to voriconazole was tested by two microdilution techniques: the National Committee for Clinical Laboratory Standards reference method M38-A and a colorimetric method, Sensititre YeastOne. The study tested a total of 244 isolates: 223 Aspergillus (136 Aspergillus fumigatus, 37 A. niger, 26 A. terreus, 16 A. flavus, 7 A. nidulans, and 1 A. ustus), 14 Fusarium (8 Fusarium moniliformis, and 6 F. oxysporum), 6 Scedosporium apiospermum, and 1 Rhizomucor pusillus strain and four control strains (Candida parapsilosis ATCC 22019, C. krusei ATCC 6258, A. fumigatus ATCC 204305, and A. flavus ATCC 204304). For all tested species except one F. moniliforme strain and R. pusillus, the MIC, the MIC at which 50% of the isolates are inhibited (MIC(50)), and MIC(90) ranges of </=1 microg/ml were obtained for voriconazole, indicating excellent activity against these species. The high rate of agreement between the two methods used (97 to 99%) suggests that the Sensititre YeastOne colorimetric method may be a valuable tool for determining the susceptibility of filamentous fungi to voriconazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.